Rafferty Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Rafferty Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,984	Closed	-$1.12M	–	1129
2025 Q4	$1.12M	Buy	+32,984	New	+$1.02M	﹤0.01%	777
2024 Q1	–	Sell	-11,444	Closed	-$2.28M	–	1095
2023 Q4	$2.28M	Sell	11,444 -826	-7%	-$102K	0.01%	640
2023 Q3	$1.63M	Sell	12,270 -3,643	-23%	-$595K	0.01%	673
2023 Q2	$2.38M	Buy	15,913 +1,983	+14%	+$309K	0.01%	599
2023 Q1	$2.04M	Sell	13,930 -4,341	-24%	-$878K	0.01%	608
2022 Q4	$2.89M	Buy	18,271 +9,370	+105%	+$1.5M	0.02%	491
2022 Q3	$1.71M	Buy	+8,901	New	+$1.68M	0.02%	545
2022 Q2	–	Sell	-10,467	Closed	-$1.84M	–	1208
2022 Q1	$1.84M	Sell	10,467 -50	-0.5%	-$9.44K	0.01%	631
2021 Q4	$3.09M	Buy	+10,517	New	+$2.81M	0.02%	530

Rafferty Asset Management's RAPT Position: Q1 2026 in Review

Rafferty Asset Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 32,984 shares — an estimated $1.12M sold.

Rafferty Asset Management first reported a position in RAPT in Q4 2021 and held it in 9 quarters. The position peaked at $3.09M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Rafferty Asset Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Rafferty Asset Management sold 32,984 RAPT Therapeutics shares in Q1 2026, an estimated $1.12M.
Rafferty Asset Management first reported a position in RAPT Therapeutics in Q4 2021 and held it in 9 quarters.
Rafferty Asset Management's RAPT Therapeutics position peaked at $3.09M in Q4 2021.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.